Figure 8. ZOL inhibits in vivo angiogenesis evaluated by matrigel plug assay. In vivo vessel formation was assessed after the injection of C57BL/6 mice with matrigel plugs containing heparin only (negative control) (a), containing heparin, VEGF and TNFα (positive control) (b), containing CG5 cells untreated (c) or previously treated with Denosumab at 100 μM (d) or ZOL at 100 μM (e) for 24 h in serum-free medium. After 5 d, animals were sacrificed and neovascularisation was evaluated by macroscopic analysis and by the measurement of Hb content of matrigel plugs. The macroscopic appearance of representative matrigel plugs from each experimental group is shown (A). Histograms represent the mean value (n = 10; data from two independent experiments) of the Hb content, expressed as absorbance (OD)/100 mg of matrigel plug. Bars: +SD values (B). Denosumab vs untreated: p = 0.08; ZOL vs. untreated p = 0.0008 (*).